Adoptive immunotherapy using zoledronate-expanded autologous gamma/delta T cells for patients with non-small cell lung cancer refractory to standard treatment.

Adoptive immunotherapy using zoledronate-expanded autologous gamma/delta T cells for patients with non-small cell lung cancer refractory to standard treatment. - Zoledronate-expanded autologous gamma/delta T cell therapy for NSCLC

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006128

Enrollment

Registered

2011-08-08

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Autologous gamma/delta T cells are injected on day0, day14, day28, day42, day56, day70.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-small cell lung cancer patients who meet the following criteria: - Refractory to standard treatment; - Life-expectancy more than 6 months; - 20 years or more; - Performance status 0-1; - No serious abnormality in bone marrow, liver and/or renal functions.

Exclusion criteria

Exclusion criteria: Patients who have: - Uncontrolled infections; - Active autoimmune diseases; - Serious cardiac disease; - Other cancers; - Received continuous systemic steroids; - Pregnant, to be pregnant, or nursing mothers; - Principle investigator or co-investigator judged to be inappropriate to participate in this study.

Design outcomes

Primary

Measure	Time frame
Progression-free survival	—

Secondary

Measure	Time frame
Safety Efficacy: - Antitumor effect; - Overall survival; - Improvement of tumor-related markers; - QOL score.	—

Countries

Japan

Contacts

Public ContactKazuhiro Kakimi

The University of Tokyo Hospital Department of Immunotherapeutics

immunotherapy-admin@umin.ac.jp03-5805-3163

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026